🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 171 of 857 · Phase 3 first, then by program name

  1. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Binge Eating Disorder

    phase 3 small molecule completed

    1 trial

  2. Sodium Thiosulfate Injection

    Shanghai University of Traditional Chinese Medicine

    Hepatoblastoma

    phase 3 small molecule active

    1 trial

  3. Sodium Zirconium Cyclosilicate (SZC)

    AstraZeneca

    Hyperkalemia

    phase 3 small molecule terminated

    1 trial

  4. Sodium chloride 0.372% solution, Dexamethasone sodium phosphate for encapsulation into autoerythrocytes

    Quince Therapeutics

    Ataxia Telangiectasia

    phase 3 small molecule active

    1 trial

  5. Sodium tetradecyl sulfate

    Hospital Authority, Hong Kong

    Gastric Varices Bleeding

    phase 3 small molecule active

    1 trial

  6. Sofosbuvir

    Gilead Sciences Ireland UC

    Chronic HCV Infection

    phase 3 small molecule completed

    1 trial

  7. Sofosbuvir

    Gilead Sciences Ireland UC

    Hepatitis C

    phase 3 small molecule completed

    2 trials

  8. Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    NovoThirteen

    Growth Hormone Deficiency in children

    phase 3 small molecule active

    1 trial

  9. Solcera, Preserved water

    Alphapharm Pty Ltd

    Actinic keratosis

    phase 3 small molecule active

    1 trial

  10. Solifenacin succinate

    Astellas Pharma Europe B. V.

    Neurogenic Detrusor Overactivity

    phase 3 small molecule completed

    1 trial

  11. Soliris 300 mg concentrate for solution for infusion, Pozelimab, Cemdisiran, Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Paroxysmal nocturnal haemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  12. Solriamfetol

    Ignis Therapeutics (Suzhou) Limited

    Sleep Apnea, Obstructive

    phase 3 small molecule completed

    1 trial

  13. Solriamfetol 150 MG

    Axsome Therapeutics

    Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

    phase 3 small molecule active

    1 trial

  14. Solriamfetol 150 mg

    Axsome Therapeutics

    Excessive Sleepiness

    phase 3 small molecule active

    1 trial

  15. Solriamfetol 150 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  16. Solriamfetol 150 mg

    Axsome Therapeutics

    ADHD

    phase 3 small molecule completed

    1 trial

  17. Solriamfetol 300 mg

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  18. Solriamfetol 75mg, 150 mg, or 300 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  19. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  20. Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection

    Lacuna Pharma Pty Ltd

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  21. Solution for injection in pre-filled syringe without Ustekinumab 90, Solution for injection without Ustekinumab 45, STELARA 45 mg solution for injection, STELARA 90 mg solution for injection in pre-filled syringe, JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  22. Somapacitan

    Novo Nordisk A/S

    Growth Hormone Deficiency in Children

    phase 3 small molecule completed

    2 trials

  23. Somatostatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gallbladder Neoplasms

    phase 3 small molecule completed

    1 trial

  24. Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources